FDA Shows Deft Touch With 1st Mobile App Enforcement

By Jeff Overley (May 22, 2013, 7:27 PM EDT) -- The U.S. Food and Drug Administration's Tuesday move to rein in a developer of iPhone urinalysis software marked a perfectly balanced foray into stronger oversight of the fledgling mobile medical apps industry, experts say, addressing frustration among app makers that already work closely with regulators while taking care not to scare off potential innovators.

Experts had complained for months that India-based Biosense Technologies Pvt. Ltd.'s uChek app, which is being sold on Apple Inc.'s App Store to screen for diabetes and urinary tract infections, was clearly a medical device and had improperly failed to seek the FDA's blessing before going to...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!